Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LBN
|
|||
| Drug Name |
TAK-981
|
|||
| Synonyms |
TAK-981; 1858276-04-6; UNII-XQ43H3V6M1; XQ43H3V6M1; Sumoylation inhibitor TAK-981; SCHEMBL17398333; LXRZVMYMQHNYJB-UNXOBOICSA-N; TAK 981; TAK981; EX-A3291; BCP30806; HY-111789; CS-0091878
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H28ClN5O5S2
|
|||
| Canonical SMILES |
CC1=C(C=C(S1)C(=O)C2=CN=CN=C2NC3CC(C(C3)O)COS(=O)(=O)N)C4C5=C(CCN4)C=CC(=C5)Cl
|
|||
| InChI |
1S/C25H28ClN5O5S2/c1-13-18(23-19-7-16(26)3-2-14(19)4-5-29-23)9-22(37-13)24(33)20-10-28-12-30-25(20)31-17-6-15(21(32)8-17)11-36-38(27,34)35/h2-3,7,9-10,12,15,17,21,23,29,32H,4-6,8,11H2,1H3,(H2,27,34,35)(H,28,30,31)/t15-,17-,21+,23+/m1/s1
|
|||
| InChIKey |
LXRZVMYMQHNYJB-UNXOBOICSA-N
|
|||
| CAS Number |
CAS 1858276-04-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03648372) A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.